N
Nyan L. Latt
Researcher at Rutgers University
Publications - 23
Citations - 557
Nyan L. Latt is an academic researcher from Rutgers University. The author has contributed to research in topics: Hepatitis C & Liver disease. The author has an hindex of 7, co-authored 21 publications receiving 471 citations. Previous affiliations of Nyan L. Latt include Kaiser Permanente & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma
Nishant Agrawal,Yuchen Jiao,Chetan Bettegowda,Susan Hutfless,Yuxuan Wang,Stefan David,Yulan Cheng,William S. Twaddell,Nyan L. Latt,Eun Ji Shin,Li-Dong Wang,Liang Wang,Wancai Yang,Victor E. Velculescu,Bert Vogelstein,Nickolas Papadopoulos,Kenneth W. Kinzler,Stephen J. Meltzer +17 more
TL;DR: Exomic sequencing on esophageal adenocarcinomas and ESCCs from the United States highlights key genetic differences and suggests that NOTCH1 is a tumor suppressor gene in the esophagus, and provides a genetic basis for the evolution of EACs from BarrettEsophagus.
Journal ArticleDOI
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Kris V. Kowdley,Vinay Sundaram,Christie Y. Jeon,Kamran Qureshi,Nyan L. Latt,Amandeep Sahota,Stephen Lott,Michael P. Curry,Naoky Tsai,Nathorn Chaiyakunapruk,Y. Lee,Jörg Petersen,Peter Buggisch +12 more
TL;DR: An 8‐week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended.
Journal Article
Hepatitis C virus and its renal manifestations: a review and update.
TL;DR: The pathophysiology of renal manifestations of chronic HCV infection is reviewed, recent insights into diagnostic and treatment options for HCV-induced glomerulopathies andHCV-infected dialysis patients are discussed, and the work-up of HCv-positive renal transplant candidates is described.
Journal ArticleDOI
Expanding indications for liver transplantation in the era of liver transplant oncology
Guergana Panayotova,Keri E Lunsford,Nyan L. Latt,Flavio Paterno,James V. Guarrera,Nikolaos Pyrsopoulos +5 more
TL;DR: In this paper, the authors evaluated liver transplantation for expanded oncologic indications such as: expanded criteria hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed tumors, and liver limited metastatic colorectal carcinomas.
Journal ArticleDOI
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma
Nicole E. Rich,Ju Dong Yang,Ponni V. Perumalswami,Naim Alkhouri,Whitney E. Jackson,Neehar D. Parikh,Neil Mehta,Reena Salgia,Andres Duarte-Rojo,Laura Kulik,Mina Rakoski,Adnan Said,Omobonike Oloruntoba,George N. Ioannou,Maarouf Hoteit,Andrew M. Moon,Amol S. Rangnekar,Sheila Eswaran,Elizabeth X. Zheng,Janice H. Jou,James Hanje,Anjana Pillai,Ruben Hernaez,Robert J. Wong,Steven Scaglione,Hrishikesh Samant,Devika Kapuria,Shaun Chandna,Russell Rosenblatt,Veeral Ajmera,Catherine Frenette,Sanjaya K. Satapathy,Parvez S. Mantry,Prasun K. Jalal,Binu John,Oren K. Fix,Michael D. Leise,Christina C. Lindenmeyer,Avegail Flores,Nayan M. Patel,Z. Gordon Jiang,Nyan L. Latt,Renumathy Dhanasekaran,Mobolaji Odewole,Sofia Kagan,Jorge A. Marrero,Amit G. Singal +46 more
TL;DR: Based on a survey sent to hepatology providers, there is variation in provider attitudes and practice patterns regarding use and timing of DAAs for patients with HCC.